Exploring New Horizons: Expanding Pharmaceutical Markets Beyond the United States

In the dynamic landscape of the pharmaceutical industry, companies are increasingly realizing that selling drugs exclusively in the United States is not the only path to international success. While the American market has traditionally been the mainstream destination for pharmaceutical expansion, emerging markets around the world are now offering lucrative opportunities for growth. This article delves into the rising trend of Chinese biotech companies and multinational pharmaceutical giants exploring alternative markets, highlighting the advantages and potential of venturing beyond the United States.

The Shifting Paradigm:

Amidst the intense competition in the PD-1 (Programmed Death-1) market, where Chinese biotech companies and multinational pharmaceutical giants battle for dominance, another form of collaboration has quietly emerged as one of the most cost-effective choices for Chinese biotech firms. On January 25th, Sino Biopharmaceutical, Converge Biotech, and Glenmark, the fourth-largest generic drug company in India, signed an agreement worth $700 million to sell the PD-L1 drug Envali (envolimab) injection in overseas emerging markets. These markets include India, the Asia-Pacific region excluding Singapore, Thailand, and Malaysia, the Middle East, Africa, the Commonwealth of Independent States, and Latin America.

The Appeal of Emerging Markets:

Emerging markets outside the United States hold a significant advantage and present abundant business opportunities. According to data from IQVIA, the average compound annual growth rate (CAGR) of pharmaceutical markets in emerging markets is projected to be 5% to 8% from 2022 to 2026, while developed market countries are anticipated to grow at a CAGR of only 2% to 5% over the same period. For patients in certain emerging markets, original drugs remain out of reach, creating a substantial demand gap that can be filled with lower-priced biosimilars. This aligns perfectly with the positioning of Chinese pharmaceutical products.

The Influence of the Belt and Road Initiative:

Under the influence of China's Belt and Road Initiative, the landscape of emerging countries has become clearer and more receptive to Chinese partnerships. Middle Eastern capital has shifted its focus from Europe and the United States to China. In September of last year, Abu Dhabi's sovereign wealth fund, Mubadala Investment Company, established an office in Beijing. The Saudi sovereign fund, with assets over 4 trillion yuan, has also accelerated its investment in China, including the field of biopharmaceuticals. According to insiders, some pharmaceutical companies have already signed contracts and are preparing to enter the Saudi market. Companies like Hengrui Medicine, Junshi Biosciences, CStone Pharmaceuticals, and Kangfang Biotech have long embarked on their journey into the Southeast Asian market.

Embracing New Opportunities:

In 2023 alone, there were 18 authorization transactions by pharmaceutical companies targeting emerging markets, although they accounted for less than one-third of the overall cross-border license-outs. Nonetheless, this number represents a significant increase compared to 2022 and 2021. Companies like Mabwell Biotech, CStone Pharmaceuticals, and Bio-Thera Solutions have set their sights on emerging markets for product authorization and expansion. Dr. Reddy's Laboratories and Junshi Biosciences, two Chinese pharmaceutical companies, have also secured authorization services for the Ukrainian market. Additionally, companies such as Clover Biopharmaceuticals, Etana Pharmaceuticals in Indonesia, and Kangda Union are actively establishing bridges for pharmaceutical companies to enter international markets. Notably, Clover Biopharmaceuticals successfully established a viable channel through vaccine exports during the COVID-19 pandemic.

Expanding Horizons:

With the intensifying competition in the PD-1 market, Chinese innovative drug companies have ventured beyond developed markets, aiming to capture opportunities in emerging countries such as India, South Africa, and Latin America. While initially targeting the European and American markets, companies like CStone Pharmaceuticals realized that emerging markets offered untapped potential with less intense competition. For example, in Ukraine, where the original drug Herceptin was not covered by health insurance, patients, despite being aware of its efficacy and reputation, could not afford its high cost. However, HLX02, a biosimilar developed by CStone Pharmaceuticals, gained traction in the market due to its reliable quality and affordable price. As the competition in the domestic PD-1 market heated up, Chinese pharmaceutical companies started to explore broader coverage alongside their pursuit of high-profit markets in Europe and the United States.

While the United States remains a major player in the global pharmaceutical industry, Chinese biotech companies and multinational pharmaceutical giants are increasingly recognizing the potential of expanding their reach beyond American shores. Emerging markets offer unique advantages, including growing pharmaceutical markets, unmet patient needs, and a receptive environment for Chinese partnerships. As the pharmaceutical landscape continues to evolve, companies that embrace the opportunities presented by these markets are likely to enjoy significant success and contribute to the global growth of the industry.